First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era

被引：11

作者：

Capelletto, Enrica ^{[1
]}

Novello, Silvia ^{[1
]}

Scagliotti, Giorgio V. ^{[1
]}

机构：

[1] Univ Turin, Dept Oncol, San Luigi Hosp, I-10043 Turin, Italy

来源：

FUTURE ONCOLOGY | 2014年 / 10卷 / 06期

关键词：

biomarkers; chemotherapy; histology; non-small-cell lung cancer; targeted therapies; PHASE-III TRIAL; VINORELBINE PLUS CISPLATIN; EML4-ALK FUSION GENE; OPEN-LABEL; SUPPORTIVE CARE; SINGLE-AGENT; WILD-TYPE; CHEMOTHERAPY; GEFITINIB; BEVACIZUMAB;

D O I：

10.2217/fon.13.247

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Lung cancer is the leading cause of cancer-related mortality worldwide in both sexes, expected to account, in the near future, for more than 30% of all cancer-related deaths. Recently, improvements in the systemic therapy of non-small-cell lung cancer according to histology and tumor molecular characteristics led to a progressive prolongation of survival, more clinically meaningful in selected groups of patients with tumors harboring specific genomic alterations. As the search for individualized therapeutic approaches could represent one of the potential ways to improve survival expectancy of non-small-cell lung cancer patients with advanced disease stage, the aim of this review is to discuss how currently to select the best front-line therapeutic strategy.

引用

页码：1081 / 1093

页数：13

共 87 条

[1]

ALBERTI W, 1995, BRIT MED J, V311, P899

[2]

[Anonymous], 2009, P 13 BIENNIAL WORLD

[3]

Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis [J].

Ardizzoni, Andrea ;

Boni, Luca ;

Tiseo, Marcello ;

Fossella, Frank V. ;

Schiller, Joan H. ;

Paesmans, Marianne ;

Radosavljevic, Davorin ;

Paccagnella, Adriano ;

Zatloukal, Petr ;

Mazzanti, Paola ;

Bisset, Donald ;

Rosell, Rafael .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (11) :847-857

[4]

AVAPERL (MO22089): Final Efficacy Outcomes for Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) Randomised to Continuation Maintenance (mtc) with Bevacizumab (bev) or Bev plus Pemetrexed (pem) After First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx) [J].

Barlesi, F. ;

de Castro, J. ;

Dvornichenko, V. ;

Kim, J. H. ;

Pazzola, A. ;

Rittmeyer, A. ;

Vikstrom, A. ;

Mitchell, L. ;

Wong, E. K. ;

Gorbunova, V. .

EUROPEAN JOURNAL OF CANCER, 2011, 47 :16-16

[5]

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers [J].

Bergethon, Kristin ;

Shaw, Alice T. ;

Ou, Sai-Hong Ignatius ;

Katayama, Ryohei ;

Lovly, Christine M. ;

McDonald, Nerina T. ;

Massion, Pierre P. ;

Siwak-Tapp, Christina ;

Gonzalez, Adriana ;

Fang, Rong ;

Mark, Eugene J. ;

Batten, Julie M. ;

Chen, Haiquan ;

Wilner, Keith D. ;

Kwak, Eunice L. ;

Clark, Jeffrey W. ;

Carbone, David P. ;

Ji, Hongbin ;

Engelman, Jeffrey A. ;

Mino-Kenudson, Mari ;

Pao, William ;

Iafrate, A. John .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (08) :863-870

[6]

Bevacizumab Safety in Patients with Central Nervous System Metastases [J].

Besse, Benjamin ;

Lasserre, Susan F. ;

Compton, Peter ;

Huang, Jane ;

Augustus, Stella ;

Rohr, Ulrich-Peter .

CLINICAL CANCER RESEARCH, 2010, 16 (01) :269-278

[7]

Bosworth A, 2013, J CLIN ONCOL, V31

[8]

Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): Systematic review and meta-analysis [J].

Botrel, Tobias Engel Ayer ;

Clark, Otavio ;

Clark, Luciana ;

Paladini, Luciano ;

Faleiros, Eneas ;

Pegoretti, Bruna .

LUNG CANCER, 2011, 74 (01) :89-97

[9]

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials - NSCLC meta-analyses collaborative group [J].

Burdett, S. ;

Stephens, R. ;

Stewart, L. ;

Tierney, J. ;

Auperin, A. ;

Le Chevalier, T. ;

Le Pechoux, C. ;

Pignon, J. P. ;

Arriagada, R. ;

Higgins, J. ;

Johnson, D. ;

van Meerbeeck, J. ;

Parmar, M. ;

Souhami, R. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) :4617-4625

[10]

Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). [J].

Camidge, D. R. ;

Bang, Y. ;

Kwak, E. L. ;

Shaw, A. T. ;

Iafrate, A. J. ;

Maki, R. G. ;

Solomon, B. J. ;

Ou, S. I. ;

Salgia, R. ;

Wilner, K. D. ;

Costa, D. B. ;

Shapiro, G. ;

LoRusso, P. ;

Stephenson, P. ;

Tang, Y. ;

Ruffner, K. ;

Clark, J. W. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

← 1 2 3 4 5 6 7 8 9 →